The management of metastatic castration-resistant prostate cancer (mCRPC) remains clinically challenging due to limited therapeutic options, treatment-associated toxicities, primary or acquired resistance to systemic hormonal therapies, limited duration of response, and the high overall mortality rate. The significance of mutations in DDR pathway genes, including BRCA1/2 and ATM, and deficits in mismatch repair have been highlighted in recent reports and further emphasized by the inclusion of recommendations for genetic counseling and testing for these alterations in the recent updates to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for prostate cancer. Emerging data from clinical studies suggest that in mCRPC inhibitors of PARP yield meaningful clinical responses and improve outcomes. Additional data pertaining to PARP inhibitors as monotherapy or in combination with other agents are anticipated to cause a paradigm shift in advanced prostate cancer management.
The AXIS symposium exposed learners to the personal insights of several experts in the field and included in-depth analyses of the cutting-edge science on the present and future role of PARP inhibitors in prostate cancer. This web-based, on-demand activity expands the reach of the live educational activity by providing the educational content to learners who were not able to attend the live event and give them the opportunity to hear from the internationally recognized experts who presented at the live event. Key topics include evidence regarding the significance and clinical use of genetic counseling and testing, the rationale for PARP inhibitors in DDR-dysfunctional prostate cancers, and completed and ongoing clinical studies evaluating PARP inhibitors in mCRPC to enable rapid and appropriate clinical uptake of this promising class of agents.